You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm was delisted from the Nasdaq during the third quarter, and reported a net loss of $29 million.
The company has received a number of warnings from the Nasdaq over the past year for its failure to meet the exchange's $35 million market value and $1 minimum bid price requirements.
The 1-for-80 split of the company's common stock, which will go into effect on Sept. 16, will reduce its outstanding shares to approximately 1 million.
The firm now has until Feb. 27, 2017 to achieve and maintain a $1 minimum list price on its shares for 10 consecutive days.
Continued growth in its customer base and the adoption of the firm's Group B Strep assay drove the increase.
For the three months ended June 30, the Salt Lake City-based firm saw a 126 percent increase in US customers, from 115 to 260.
With the exception of $6 million available to the company immediately, the remainder will be distributed over 15 months beginning in February 2017.
The previously FDA-approved test uses PCR to detect Shiga toxin-producing Escherichia coli and serotype O157 directly from patient specimens.
The company was told in October that it was not in compliance with continued listing rules, and it also received a notice of potential delisting in April.
Two of the firm's assays were evaluated in posters presented at a recent conference, demonstrating good performance relative to commonly used non-molecular methods.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.